Notably, cemiplimab monotherapy is already indicated for use (in the United States and in the European Union) as a first-line therapy for adult patients with NSCLC and high PD-L1 expression (≥50% of tumour cells), but without EGFR, ALK, or ROS1 aberrations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.